CCR5

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

CytoDyn
CytoDynVANCOUVER, WA
1 program
1
700mg leronlimab weekly dosePhase 21 trial
Active Trials
NCT05730673Withdrawn0Est. Aug 2023

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
CytoDyn700mg leronlimab weekly dose

Clinical Trials (1)

NCT05730673CytoDyn700mg leronlimab weekly dose

Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer

Start: Sep 2022Est. completion: Aug 20230
Phase 2Withdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space